Interferon-alpha (IFN-a) has strong antitumor effects, and IFN-a gene therapy has been used clinically against some cancers. In this study, we evaluated the efficacy of the combination of IFN-a-transduced tumor cell vaccines and programmed cell death 1 (PD-1) blockade, and investigated the mechanisms of the antitumor effects of the combined therapy. A poorly immunogenic murine colorectal cancer cell line, MC38, was transduced to overexpress IFN-a. In a therapeutic model, parental tumor-bearing mice were inoculated with MC38-IFNa cells and an anti-PD-1 antagonistic antibody. Analyses of immunohistochemistry and tumor-specific lysis were performed. The outgrowth of the established tumors was significantly reduced in mice treated with the combination of IFN-a and anti-PD-1. Immunohistochemical analyses of the therapeutic model showed marked infiltration of CD4 þ cells and CD8 þ cells in the established MC38 tumors of mice treated with both IFN-a and anti-PD-1. Significant tumorspecific cytolysis was detected when splenocytes of mice that were treated with both IFN-a and anti-PD-1 were used as effector cells. These results suggest that blockade of the PD-1 PD-ligand enhanced the Th1-type antitumor immune responses induced by IFN-a. The combination of IFN-a gene-transduced tumor cell vaccines and PD-1 blockade may be a possible candidate for a cancer vaccine for clinical trials.
INTRODUCTION
Cellular immune responses are thought to be impaired in patients with advanced malignant tumors, and tumors are thought to escape immune surveillance of patients by several mechanisms. 1, 2 To overcome the immune suppression or immune escape of patients with malignant tumors, novel approaches for inducing a strong cellular immune response are needed in such patients. Several studies have revealed that the cytokine gene transduction of tumor cells induces potent antitumor immune responses without systemic adverse effects in murine models. The subcutaneous injection of the transduced cells can induce a local inflammation at the site of tumor by the accumulation of inflammatory cells, such as activated natural killer (NK) cells, macrophages, dendritic cells and T lymphocytes. 3--6 As a result of these phenomena, the clinical application of a vaccination using gene-transduced tumor cells as a vehicle to deliver cytokines is attractive.
Interferon-alpha (IFN-a) has many biologic effects, including the enhancement of IFN-a/b production, 7, 8 an antiviral function, the inhibition of cell growth and antiangiogenesis. 9 IFN-a upregulates the expression of major histocompatibility complex class I molecules on the cell surface, enhances the proliferation of type-I helper T cells (Th1), 10 and has an important role in the generation of cytotoxic T lymphocytes (CTLs) in specific antitumor immune responses. 11 We previously reported that IFN-a-expressing tumor cells promote the survival of tumor-specific CTLs by preventing apoptosis, 12 and in addition, the combination of IFN-a gene therapy and either interleukin (IL)-4 or IL-12 gene therapy was found to suppress the outgrowth of established tumors. 13, 14 Based on these immunomodulating effects of IFN-a, it has been used to treat patients with tumors, such as melanoma, renal cell carcinoma and leukemia. The programmed cell death-1 (PD-1) protein was first described as a member of the B7 family of costimulatory molecules that modulate T-cell antigen-specific receptor signaling and control Tcell activation, inactivation and survival. 15 Recently, PD-1 has been identified as a marker of exhausted T cells in chronic infectious disease. 16--22 Among the numerous mechanisms of tumor-induced immunosuppression by which tumors can escape from immune surveillance, a number of studies have suggested a role of the interaction between PD-1 and the programmed death-ligand 1 (PD-L1) in inhibiting the effector functions of antigen-specific CD8 þ T cells. 23--26 PD-1 is expressed on tumor-infiltrating CD8 þ T cells in tumors or on antigen-specific CD8 T cells in hosts with tumors, and the function of these PD-1 þ T cells is impaired. 27, 28 PD-L1 is expressed at high levels in several different cancers, 29 and the high levels of expression of PD-L1 on tumors is strongly associated with poor prognosis. 30, 31 A recent study showed that the blockade of PD-1--PD-L signaling restored functional T-cell responses in several cancers and, subsequently, improved clinical outcomes. 32--34 In this study, the antitumor effects of the combination of IFN-atransfected tumor cell vaccine therapy and PD-1 blockade were evaluated in a poorly immunogenic murine colorectal cancer system as a preliminary investigation of the combined therapy before clinical studies. We show that, when parental tumorbearing mice were injected with IFN-a-overexpressing tumor cells and anti-PD-1 blocking antibody, the outgrowth of the established parental tumors was significantly suppressed. Furthermore, in order to explore the mechanisms of the antitumor effects induced by IFN-a and anti-PD-1 combination therapy, we performed immunohistologic staining of the tumors and tried to induce tumor-specific T lymphocytes.
MATERIALS AND METHODS Mice
Female 6-week-old C57BL/6 (B6) mice were purchased from Sankyo Lab Service (Tokyo, Japan) for use in experiments from 8 to 12 weeks of age. Mice were maintained in an animal care facility at Showa University. This study was approved by the ethical committee for Animal Experiments of Showa University (permission #2011-1111).
Cell lines, culture medium and reagents
The MC38 murine colorectal adenocarcinoma cell line, the MCA205 fibrosarcoma cell line (both B6 mouse origin) and yeast artificial chromosome-1 (YAC-1) lymphoma cells were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM Lglutamine, 100 IU ml --1 penicillin, 100 mg ml --1 streptomycin, 10 mM HEPES buffer, 1 mM minimum essential medium sodium pyruvate and 0.1 mM minimum essential medium nonessential amino acids (complete medium) in a humidified incubator with 5% CO 2 in air at 37 1C. All cell culture reagents were purchased from Life Technologies (Gaithersburg, MD). YAC-1 cells were used as target cells in order to assess the nonspecific killing in cytolytic assays.
The MC38 cell line was genetically modified in order to produce murine IFN-a (MC38-IFNa), as described previously. 35 The expression of IFN-a was confirmed by enzyme-linked immunosorbent assay (ELISA) using a commercially available kit according to the manufacturer's instructions (mouse IFN-a ELISA, PBL InterferonSource, New Brunswick, NJ). MC38 cells expressing the neomycin-resistance gene following retroviral transduction with MFG-Neo (MC38-Neo) were used as control cells. 35 Gamma-irradiation (100 Gy for tumor cells) was performed with Gammacell 3000 Elan (Nordion, Kanata, ON, Canada). As reported previously, 1 Â ) were harvested from these mice on day 35 and then incubated in the presence of irradiated (100 Gy) and genetically modified MC38 (2 Â 10 5 cells ml --1 ) or 10 mg ml --1 of anti-PD-1 antagonistic antibody (BioLegend, San Diego, CA) either alone or in combination in complete medium. Cells were harvested every 3 days, and cell numbers were determined microscopically. IFN-g and IL-10 production of splenocytes from immunized mice were observed. After 3 days of incubation, IFN-g and IL-10 concentrations in the culture supernatant were measured by ELISA using a commercially available kit according to the manufacturer's instructions (mouse IFN-g ELISA and mouse IL-10 ELISA, R&D Systems, Minneapolis, MN).
Flow cytometric analyses of lymphocytes from immunized mice stimulated with a genetically modified MC38 or anti-PD-1 antibody
In order to observe the immunogenic effects of IFN-a and anti-PD-1 antibody, flow cytometric analyses was performed using FACSCalibur (Nippon Becton Dickinson, Tokyo, Japan). After 7 days of in vitro incubation, splenocytes from MC38-IFNa immunized mice were harvested.
CD4
þ and CD8 þ T cells were separated from splenocytes using CD4 and CD8 microbeads (MACS system; Miltenyi Biotec, Bergisch Gladbach, Germany), and isolated using an autoMACS Pro Separator (Miltenyi Biotec). These cells were stained with fluorescein isothiocyanate-conjugated and phycoerythrin-conjugated monoclonal antibodies. The monoclonal antibodies used in this assay were anti-H-2K b , CD4, CD8, CD25, 7-AAD (obtained from Nippon Becton Dickinson) and caspase-8 (Medical and Biological Laboratories, Nagoya, Japan) antibodies.
Therapeutic models
In order to evaluate the potential to treat established tumors, we measured the size of established WT tumors of mice treated with genetically modified MC38 cells and antibody, as previously described. 35 In brief, B6 mice were injected subcutaneously with 1 Â 10 5 MC38-WT cells in the right flank. In all, 7, 10 and 14 days after the WT inoculation, treatment was performed following the injection of 1 Â 10 5 genetically modified MC38 or 200 mg of anti-PD-1 antibody either alone or in combination into the contralateral (left) flank. Each experiment involved six mice per group. Tumor size was measured twice a week using vernier calipers. Experiments with the therapeutic model were performed three times.
In vivo antibody-mediated depletion of leukocytes
To determine the role of the immune system in reduction of tumor growth in vivo, CD4 þ T cells, CD8 þ T cells or NK cells were depleted as reported previously. 13 Culture medium of hybridomas producing the following antibodies was used at appropriate dilutions/concentrations: anti-CD4 (GK1.5, TIB207; American Type Culture Collection (ATCC), Manassas, VA), anti-CD8 (2.43, TIB210; ATCC) and anti-asialo-GM1 (anti-NK cells; WAKO, Osaka, Japan). All antibody doses and treatment regimens have been identified for the same batch of antibodies used in preliminary studies. Mice were inoculated with 1 Â 10 5 cells of MC38-WT 3 days after depletion of leukocytes, and MC38-IFNa and anti-PD-1 antibody combination treatment were performed 7, 10 and 14 days after the WT inoculation. This treatment was confirmed to completely delete the desired cell population for the entire duration of the study, as determined by flow cytometric analysis (data not shown).
Immunohistologic analysis ). Seven days later, responder cells (1 Â 10 6 cells ml --1 ) were restimulated with irradiated MC38-IFNa tumor cells (100 Gy, 1 Â 10 5 cells ml --1 ) and syngeneic dendritic cells (2 Â 10 5 cells ml --1 ) in the presence of 50 IU ml --1 of recombinant mouse IL-2 (R&D Systems). Dendritic cells were generated from bone marrow cells of B6 mice using murine granulocyte-macrophage colony-stimulating factor (10 ng ml --1 ) and IL-4 (10 ng ml --1 ) that was obtained from PeproTech EC (London, England), as reported previously. 36 Cytolytic assays were performed 7 days after the last stimulation using the responder cells as effector cells. 3 ) and various numbers of effector cells at the indicated effector to target ratios (E:T) were plated in 200 ml of complete medium in each well of the 96-well round-bottom plates. 51 Crrelease was measured after a 4-h incubation at 37 1C. The percent lysis was determined using the formula (release in assayÀspontaneous release) Â 100/(maximum releaseÀspontaneous release). Maximum release was determined by the lysis of labeled target cells with 1% Triton X-100. Spontaneous release was measured by incubating target cells in the absence of effector cells and was o15% of maximum release.
Cytolytic assays

Statistical analyses
Statistical analyses were carried out using means s.d., one-way analysis of variance and Turkey's honestly significant difference post-hoc test. Differences between groups were considered significant when the P values were o0.05.
RESULTS
Anti-PD-1 antibody and IFN-a-overexpressing cells enhanced IFN-g production and reduced IL-10 production by splenocytes from mice immunized with MC38-IFNa First, we observed the in vitro effects of MC38-IFNa and the anti-PD-1 antibody. Mice were initially inoculated with MC38-IFNa three times. Subsequently, these mice received challenges of MC38-WT cells 14 days after the last immunization. One week later, splenocytes of the treated mice were harvested and stimulated with the MC38-IFNa or anti-PD-1 antibody in vitro. þ or CD8 þ population. These experiments were repeated three times, and a representative result is shown.
the supernatant of each culture were measured by ELISA. IFN-g production was clearly increased in the IFN-a and anti-PD-1 antibody-stimulated group compared with controls (IFN þ anti-PD-1 vs control, P ¼ 0.009; Figure 1a ), whereas IL-10 production was suppressed significantly (Po0.001, Figure 1a ). In addition, the proliferation rate of the splenocytes did not differ significantly between the control group and the treatment groups (data not shown). These results suggest that IFN-a and anti-PD-1 elicited a potent Th1-type response. (Figure 2b ). On the other hand, depletion of NK cells did not affect to the tumor suppression. These results suggest that both CD4 þ and CD8 þ T cells are responsible for antitumor response in mice treated with IFN-a and anti-PD-1. Figure 4b ). These findings suggest that anti-PD-1 has a minimal ability to induce tumor-specific cytotoxicity, but it can enhance the strong specific response that is induced by IFN-a.
DISCUSSION
Gene therapy using tumor cells that are genetically modified to produce cytokines has been studied in several therapeutic models. We have previously reported that the combination of IFN-a genetransduced tumor-based vaccination therapy and IL-4 or IL-12 gene therapy suppresses the outgrowth of established tumors. 13, 14 Although the suppressive effects of established tumors were observed in these cytokine combination therapy models, we did not see reductions in the size of all of the parental tumors. Therefore, further improvements in the treatment are needed before clinical application. In addition, we focused on PD-1, which has been identified as a marker of exhausted T cells. 16--22 As a blockade of PD-1 signaling has been shown to improve clinical outcome and restore functional T-cell responses in cancers, 32--34 we hypothesized that the PD-1 blockade had potential to enhance the Th1 responses elicited by the IFN-a gene-transduced tumorbased vaccination therapy. In this study, we investigated the antitumor effects and mechanisms of the combination of the IFN-a-transduced tumor cell vaccine therapy and PD-1 blockade. First, we examined the in vitro effects of the IFN-a-transduced tumor cells and the anti-PD-1 antibody in a culture medium of splenocytes. Both IFN-a and the blockade of PD-1 obviously increased IFN-g production and suppressed IL-10 production, and additive effects were observed with the combination of IFN-a and anti-PD-1. These results suggest that IFN-a and anti-PD-1 promoted Th1-type antitumor immune responses, and the responses were enhanced in cooperation with each other. From these results of the in vitro additive antitumor effects, we tried to treat tumor-bearing mice with the IFN-a and anti-PD-1 antibody, and a significant suppression of the outgrowth of the established tumors was observed only in the combination treatment group. The IFN-a or anti-PD-1 single therapy groups showed a weak, but not significant suppression of the established tumors compared with the control group. Leukocyte depletion þ T cells, CD8 þ T cells or asialo-GM1 þ cells using specific antibodies 3 days before the WT tumor inoculation. MC38-IFNa and anti-PD-1 antibody combination therapy was performed every third day starting 7 days after WT tumor injection. Six mice were studied in each group. The results are reported as mean tumor area (mm 2 ) ±s.e. Significance at the 95% confidence limits is indicated. This experiment was performed twice with similar results. experiments demonstrated that both CD4 þ T cells and CD8 þ T cells were essential to the tumor suppression induced by combination therapy. In contrast, the depletion of NK cell did not affect to the therapeutic effect in this model.
Immunohistologic analyses of the established tumors in the mice that were treated with anti-PD-1 showed marked infiltration of both CD4 þ cells and CD8 þ cells compared with controls and the group treated with MC38-IFNa alone. These data support the results of a previous study that showed that blockade of PD-1 signaling pathways reversed T-cell exhaustion and restored antitumor immunity. 34 Interestingly, the proliferation rate of splenocytes did not differ significantly between the control group and the anti-PD-1 treatment groups in the in vitro culture setting (data not shown). The conditions and microenvironment of the local tumor sites seemed to lead to this discrepancy between the in vitro and in vivo results because immunohistochemical staining confirmed that established MC38-WT tumors expressed abundant PD-L1 molecules (data not shown). However, we demonstrated that blockade of PD-1 reduced the level of apoptosis in lymphocytes on in vitro setting. These observations suggest that the PD-1 blockade prevented the apoptosis of lymphocytes and maintained the survival and infiltration of tumor-specific T cells in the local tumor environment, which strongly expressed PD-L1 molecules.
Although the PD-1 blockade recruited lymphocytes to the tumor sites, the therapeutic effects were not remarkable for the treatment with anti-PD-1 alone. In order to assess this result, we tried to induce tumor-specific CTLs from the splenocytes of IFN-a or anti-PD-1-treated mice and then perform cytolytic assays. A high specificity for MC38 was observed when treatment was performed with IFN-a, whereas only nonspecific cytolysis was detected with the anti-PD-1 treatment. Furthermore, specific cytolysis against MC38 was observed more potently with the combined IFN-a and anti-PD-1 treatment group compared with the IFN-a single treatment group. These observations suggest that IFN-a elicited tumor-specific CTLs, whereas the blockade of PD-1 mainly maintained the specific response induced by IFN-a, preventing CTLs from apoptosis. Thus, the combined therapy is considered to be reasonable because both IFN-a and the blockade of PD-1 revealed antitumor effects by different mechanisms. Also recent study show similar results and support our study that blockade of PD-1 can enhance the immune response stimulated by cytokine therapy in murine colon cancer model. high amount of IFN-a, would be difficult in the clinical setting. Administering recombinant IFN-a repetitively seems to be simple, but there was no therapeutic effect observed in our past study (data not published). In order to facilitate this, the method of cytokine gene delivery will need to be modified. In addition, it is not established whether anti-PD-1 therapy is effective against the tumors, which are negative for the expression of PD-L1. In order to resolve these problems, we are now planning to use other tumor cell lines and reevaluate the antitumor effects of the PD-1 blockade on the established tumors.
In conclusion, our findings suggest that the combination of IFN-a immunotherapy and PD-1 blockade therapy has potential for inducing potent immune responses and that this might be considered as a possible candidate for clinical trials of cancer vaccines, although further investigations are required.
